The reverse split is a technical event; the real catalyst is the Redx Pharma acquisition. Traders should monitor the upcoming proxy statement filing and the special meeting vote, as stockholder approval is required to close the deal. The reverse split date (Aug 24) may cause short-term volatility as the market adjusts to the new share price, but the long-term thesis hinges on the Redx transaction closing.
Price Chart
Executive Summary
Skye Bioscience filed a DEFA14A to announce the effective date of its previously disclosed 1-for-8 reverse stock split, set for August 24, 2026, as part of its efforts to regain Nasdaq compliance. This filing is a procedural step in the broader transformative acquisition of Redx Pharma, which will fundamentally change Skye's business and capital structure. The reverse split is a technical event that does not alter the company's fundamentals but is necessary to maintain its listing ahead of the Redx deal.
Key Facts
- The 1-for-8 reverse stock split will become effective at 12:01 am New York time on Thursday, August 24, 2026.
- Common stock will begin trading on a split-adjusted basis at market open on August 24, 2026, under the same ticker symbol SKYE.
- The new CUSIP number for the common stock following the reverse split is 83086J309.
- This filing is an amendment to the Original Form 8-K filed August 14, 2026, which disclosed the transaction agreement to acquire Redx Pharma Limited.
- The reverse split is intended to help Skye regain compliance with Nasdaq's minimum bid price requirement.
Financial Impact
The reverse stock split is a mechanical adjustment with no change to the company's market capitalization or enterprise value. The transaction to acquire Redx Pharma values Redx at $161 million and includes a concurrent $125 million PIPE.
Risk Factors
- The Redx acquisition may not close if stockholder approval is not obtained or other closing conditions are not satisfied.
- The reverse split may not be sufficient to maintain Nasdaq listing if the post-split share price does not stay above $1.00.
- Current SKYE shareholders face significant dilution and a change of control, with Redx designating the post-closing board and management.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-058121 |
| Document: 0001628280-26-058121-index-headers.html | 0001628280-26-058121 |
| Document: 0001628280-26-058121-index.html | 0001628280-26-058121 |
| Document: 0001628280-26-058121.txt | 0001628280-26-058121 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | DEFA14A | $0.2809 $1.77 | ▲ +528.34% | ▲ +528.34% | $1.68 (+498.08%) |
Aug 14, 2026 7w ago | 8-K | $0.5015 $1.99 | ▲ +296.81% | ▲ +298.80% | $1.68 (+235.00%) |
Aug 14, 2026 7w ago | Press Release | $0.5015 $1.99 | ▼ −296.81% | ▼ −298.80% | $1.68 (−235.00%) |
May 15, 2026 20w ago | 8-K | $0.7780 $0.7184 | ▲ +7.66% | ▲ +9.24% | $1.68 (−115.94%) |
May 12, 2026 20w ago | Press Release | $0.8140 $0.7800 | ▲ +4.18% | ▲ +2.45% | $1.68 (−106.39%) |
Apr 29, 2026 22w ago | 3 | $0.8940 $0.8500 | ▼ −4.92% | ▼ −10.97% | $1.68 (+87.92%) |
Apr 16, 2026 24w ago | DEFA14A | $0.7500 $0.8200 | ▲ +9.33% | ▲ +3.52% | $1.68 (+124.00%) |
Apr 2, 2026 26w ago | Press Release | $0.6980 $0.8790 | ▲ +25.93% | ▲ +16.05% | $1.68 (+140.69%) |
Mar 10, 2026 29w ago | Press Release | $0.7210 $0.7260 | ▲ +0.69% | ▲ +0.17% | $1.68 (+133.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access